Document is current

Article History

Received: 19 February 2024

Accepted: 6 September 2024

First Online: 10 October 2024

Declarations

:

: The studies reported herein were conducted in accordance with the International Council for Harmonisation (ICH) guidelines, applicable regulations, and guidelines governing clinical study conduct and the ethical principles that have their origin in the Declaration of Helsinki. Approval was granted by institutional review boards and independent ethics committees at participating institutions.

: All participants provided written consent prior to participation or study-related procedures.

: All individual participants signed informed consent regarding publishing their data.

: MB, BE, ED, RMM, and AHS are employees of AbbVie and may hold AbbVie stock or options. RD is a paid consultant at Genentech/Roche and may hold Genentech/Roche stock or stock options. JLK receives research funding for clinical trials from AbbVie, Amgen, Allogene, Astra-Zeneca, BMS, Carsgen, GSK, Janssen, Novartis, Roche-Genentech, Takeda, Regeneron, Molecular Templates and participates on the advisory board/provides consulting with no personal payments for AbbVie, Amgen, BMS, Janssen, Roche-Genentech, Takeda, Astra-Zeneca, Bluebird Bio, Epizyme, Secura Biotherapeutics, Monterosa therapeutics, Trillium, Loxo Oncology, K36, Sanofi, ArcellX, and (with personal payment) Oncopeptides, Beigene, Antengene.